ClinicalTrials.gg

Program

itareparib

Its studies are mostly in Ovarian Neoplasms · Small Cell Lung Carcinoma · Glioblastoma · Carcinoma, Ovarian Epithelial, led by Nerviano Medical Sciences.

Furthest: phase 2, since May 21, 20214 company-led studies, 2 open or runningNext primary completion: May 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nerviano Medical Sciences42 open or runningphase 2since May 21, 2021Nov 12, 2019May 30, 2027phase 2 · NCT04910022

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 12, 2019First study: phase 1 study in Carcinoma, Ovarian EpithelialFirst studyNCT04182516 · 52 enrolled · United States, Bulgaria, China and more
  2. May 21, 2021Phase 2 study in GlioblastomaNCT04910022 · 150 enrolled · United States, Italy, Netherlands and more
  3. Apr 4, 20252 phase 1 studiesNCT06931626, NCT06930755

Ahead

  1. May 30, 2027Primary completion: phase 2 study in GlioblastomaNCT04910022

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06930755Ovarian Neoplasms · United States1TerminatedAug 17, 20261
NCT06931626Small Cell Lung Carcinoma · United States1RecruitingOct 30, 202610
NCT04910022Glioblastoma · United States, Italy, Netherlands and more2Active, not recruitingMay 30, 2027150
NCT04182516Carcinoma, Ovarian Epithelial · United States, Bulgaria, China and more1TerminatedMar 31, 202352

How it is read

Names in the registry

  • “NMS-03305293”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.